1. Αποθετήριο Παραδοτέων Υποτρόφων Δράσεων ΕΣΠΑ Τριτοβάθμιας Εκπαίδευσης 2017-2023
2. Όλο το Αποθετήριο
3. Ερευνητικές ομάδες

Τύπος:	Άρθρο σε επιστημονικό περιοδικό
Τίτλος:	Current and emerging reconstituted HDL-apoA-I and HDL-apoE approaches to treat atherosclerosis
Συγγραφέας:	[EL] Βαλάντη, Ευταξία-Κωνσταντίνα[EN] Valanti, Eftaxia-Konstantina [EL] Δαλακούρα-Καραγκούνη, Αικατερίνη[EN] Dalakoura-Karagkouni, Aikaterini [EL] Σανούδου, Δέσποινα[EN] Sanoudou, Despina
Ημερομηνία:	03/10/2018
Περίληψη:	Atherosclerosis affects millions of people worldwide. However, the wide variety of limitations in the current therapeutic options leaves much to be desired in future lipid-lowering therapies. For example, although statins, which are the first-line treatment for coronary heart disease (CHD), reduce the risk of cardiovascular events in a large percentage of patients, they lead to optimal levels of low density lipoprotein-cholesterol (LDL-C) in only about one-third of patients. A new promising research direction against atherosclerosis aims to improve lipoprotein metabolism. Novel therapeutic approaches are being developed to increase the levels of functional high density lipoprotein (HDL) particles. This review aims to highlight the atheroprotective potential of the in vitro synthesized reconstituted HDL particles containing apolipoprotein E (apoE) as their sole apolipoprotein component (rHDL-apoE). For this purpose, we provide: (1) a summary of the atheroprotective properties of native plasma HDL and its apolipoprotein components, apolipoprotein A-I (apoA-I) and apoE; (2) an overview of the anti-atherogenic functions of rHDL-apoA-I and apoA-I-containing HDL, i.e., natural HDL isolated from transgenic Apoa1-/- × Apoe-/- mice overexpressing human apoA-I (HDL-apoA-I); and (3) the latest developments and therapeutic potential of HDL-apoE and rHDL-apoE. Novel rHDL formulations containing apoE could possibly present enhanced biological functions, leading to improved therapeutic efficacy against atherosclerosis.
Γλώσσα:	Αγγλικά
Σελίδες:	12
DOI:	10.3390/jpm8040034
ISSN:	2075-4426
Θεματική κατηγορία:	[EL] Μοριακή ιατρική[EN] Molecular Medicine [EL] Βιολογία[EN] Biological sciences
Λέξεις-κλειδιά:	apolipoprotein A-I; apolipoprotein E; atherosclerosis; lipoprotein metabolism; reconstituted HDL
Κάτοχος πνευματικών δικαιωμάτων:	© 2018 by the authors. Licensee MDPI
Όροι και προϋποθέσεις δικαιωμάτων:	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Διατίθεται ανοιχτά στην τοποθεσία:	https://pubmed.ncbi.nlm.nih.gov/30282955/
Ηλεκτρονική διεύθυνση του τεκμηρίου στον εκδότη:	https://www.mdpi.com/2075-4426/8/4/34
Ηλεκτρονική διεύθυνση περιοδικού:	https://www.mdpi.com/journal/jpm
Τίτλος πηγής δημοσίευσης:	Journal of Personalized Medicine
Τεύχος:	4
Τόμος:	8
Σελίδες τεκμηρίου (στην πηγή):	Article no 34
Σημειώσεις:	(This article belongs to the Special Issue Personalized and Targeted Atherosclerosis Treatments) This research was funded in the context of the project “In vitro and in vivo evaluation of the atheroprotective role of reconstituted HDL containing apolipoprotein E3” (MIS 5006782) under the call for proposals “Supporting researchers with emphasis on new researchers” (EDULLL 34). The project is co-financed by Greece and the European Union (European Social Fund- ESF) by the Operational Programme Human Resources Development, Education and Lifelong Learning 2014–2020.
Εμφανίζεται στις συλλογές:	Ερευνητικές ομάδες